Role of endothelin in mediating postmenopausal hypertension in a rat model

American Journal of Physiology - Regulatory Integrative and Comparative Physiology

Volumn 288, Issue 1 57-1, 2005, Pages

  Yanes, Licy L ^a   Romero, Damian G ^a   Cucchiarelli, Valeria E ^a   Fortepiani, Lourdes A ^a   Gomez Sanchez, Celso E ^a   Santacruz, Francisco ^b   Reckelhoff, Jane F ^a  

^a UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

^b National Hospital of Paraguay   (Paraguay)

Author keywords

ETA receptor; ETB receptor; Kidney

Indexed keywords

ATRASENTAN; ENDOTHELIN; ENDOTHELIN 1; ENDOTHELIN A RECEPTOR; ENDOTHELIN A RECEPTOR ANTAGONIST; MESSENGER RNA; PREPROENDOTHELIN 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CAUSE OF DEATH; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; HYPERTENSION; KIDNEY CORTEX; KIDNEY MEDULLA; MENOPAUSAL SYNDROME; NONHUMAN; POSTMENOPAUSAL HYPERTENSION; PRIORITY JOURNAL; RAT; SPONTANEOUSLY HYPERTENSIVE RAT;

ANIMALS; ENDOTHELIN-1; ENDOTHELINS; FEMALE; GENE EXPRESSION; HYPERTENSION; KIDNEY CORTEX; POSTMENOPAUSE; PYRROLIDINES; RATS; RATS, INBRED SHR; RECEPTOR, ENDOTHELIN A; RNA, MESSENGER;

EID: 11144231572     PISSN: 03636119     EISSN: None     Source Type: Journal    
DOI: 10.1152/ajpregu.00697.2003     Document Type: Article

References (27)

1. Abe Y, Nakayama K, Yamanaka A, Sakurai T, and Goto K. Subtype-specific trafficking of endothelin receptors. J Biol Chem 275: 8664-8671, 2000.
2. Alexander BT, Cockrell KL, Rinewalt AN, Herrington JN, and Granger JP. Enhanced renal expression of preproendothelin mRNA during chronic angiotensin II hypertension. Am J Physiol Regul Integr Comp Physiol 280: R1388-R1392, 2001.
3. Ballew JR and Fink GD. Role of ETA receptors in experimental ANG II-induced hypertension in rats. Am J Physiol Regul Integr Comp Physiol 281: R150-R154, 2001.
4. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72: 248-254, 1976.
5. Burl VL, Whelton P, Roccella EJ, Brown C, Cutler JA, Higgins M, Horan MJ, and Labarthe D. Prevalence of hypertension in the US adult population. Results from the Third National Health and Nutrition Examination Survey, 1988-1991. Hypertension 25: 305-313, 1995.
6. Clozel M, Loffler BM, Hilfiger L, Maire JP, and Butscha B. Down-regulation of endothelin receptors by autocrine production of endothelin-1. Am J Physiol Cell Physiol 265: C188-C192, 1993.
7. David FL, Carvalho MH, Cobra AL, Nigro D, Fortes ZB, Reboucas NA, and Tostes RC. Ovarian hormones modulate endothelin-1 vascular reactivity and mRNA expression in DOCA-salt hypertensive rats. Hypertension 3:8: 692-696, 2001.
8. D'Orleans-Juste P, Labonte J, Bkaily G, Choufani S, Plante M, and Honore J. Function of the endothelin (B) receptor in cardiovascular physiology and pathophysiology. Pharmacol Ther 95: 221-230, 2002.
9. Dunnett CW. A multiple comparison procedure for comparing several treatments with a control. J Am Statist Assoc 50: 1096-1121, 1955.
10. Ergul A, Shoemaker K, Puett D, and Tackett RL. Gender differences in the expression of endothelin receptors in human saphenous veins in vitro. J Pharmacol Exp Ther 285: 511-517, 1988.
11. Fortepiani LA, Zhang H, Racusen LC, Roberts LJ II, and Reckelhoff JF. Characterization of an animal model of postmenopausal hypertension in SHR. Hypertension 41: 460-463, 2003.
12. Granger JP. Endothelin. Am J Physiol Regul Integr Comp Physiol 285: R298-R301, 2003.
13. Helmersson J, Mattsson P, and Basu S. Prostaglandin F(2α) metabolite and F2-isoprostane excretion in migraine. Clin Sci (Lond) 102: 39-43, 2002.
14. Kaehler J, Sill B, Koester R, Mittmann C, Orzechowski HD, Muenzel T, and Meinertz T. Endothelin-1 mRNA and protein in vascular wall cells is increased by reactive oxygen species. Clin Sci (Lond) 103: 176S-178S, 2002.
15. Komatsumoto S and Nara M. Changes in the level of endothelin-1 with aging. Nippon Ronen Igakkai Zasshi 32: 664-669, 1995.
16. Morey AK, Razandi M, Pedram A, Hu RM, Prins BA, and Levin ER. Oestrogen and progesterone inhibit the stimulated production of endothelin-1. Biochem J 330: 1097-1105, 1998.
17. Reckelhoff JF, Zhang H, and Granger J-P. Testosterone exacerbates hypertension and reduces pressure-natriuresis in male spontaneously hypertensive rats. Hypertension 31: 435-439, 1998.
18. Reckelhoff JF, Zhang H, Srivastava K, Roberts LJ II, Morrow JD, and Romero JC. Subpressor doses of angiotensin II increases plasma F2-isoprostanes in rats. Hypertension 35: 476-479, 2000.
19. Rozen S and Skaletsky HJ. Primer3 on the-www for general users and for biologist programmers. In: Bioinformatics Methods and Protocols: Methods in Molecular Biology, edited by Krawetz S and Misener S. Totowa, NJ: Humana, 2000, p. 365-386.
20. Rubanyi G and Polokoff M. Endothelins: molecular biology, biochemistry, pharmacology, physiology and pathophysiology. Pharmacol Rev 46: 325-415, 1994.
21. Sasser JM, Pollock JS, and Pollock DM. Renal endothelin in chronic angiotensin II hypertension. Am J Physiol Regul Integr Comp Physiol 283: R243-R245, 2002.
22. Schiffrin EL, Turgeon A, and Deng LY. Effect of chronic ETA-selective endothelin receptor antagonism on blood pressure in experimental and genetic hypertension in rats. Br J Pharmacol 121: 935-940, 1997.
23. Webb CM, Ghatei MA, McNeill JG, and Collins P. 17β-Estradiol decreases endothelin-1 levels in the coronary circulation of postmenopausal women with coronary artery disease. Circulation 102: 1617-1622, 2000.
24. Wiinber N, Hoegholm A, Christensen HR, Bang LE, Mikkelsen KL, Nielsen PE, Svendsen TL, Kampmann JP, Madsen NH, and Bentzon MW. 24-h Ambulatory blood pressure in 352 normal Danish subjects, related to age and gender. Am J Hypertens 8: 978-986, 1995.
25. Wilcox J, Hatch I, Gentzshein E, Stanczyk E, and Lobo R. Endothelin levels decrease after oral and nonoral estrogen in postmenopausal women with increases cardiovascular risk factors. Fertil Steril 67: 273-277, 1997.
26. Wilkins FC, Alberola A, Mizelle HL, Opgenorth TJ, and Granger JP. Systemic hemodynamics and renal function during long-term pathophysiological increases in circulating endothelin. Am J Physiol Regul Integr Comp Physiol 268: R375-R381, 1995.
27. Wong JR. Pharmacology of endothelin receptor antagonists ABT-627, ABT-546, A-182086 and A-192621: in vitro studies. Clin Sci (Lond) 48: 107S-111S, 2002.